200 related articles for article (PubMed ID: 33209658)
1. Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer.
Liu Y; Jiang H
Transl Androl Urol; 2020 Oct; 9(5):1937-1944. PubMed ID: 33209658
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.
Liu Y; Yang C; Zhang Z; Jiang H
Front Oncol; 2021; 11():679712. PubMed ID: 34221998
[TBL] [Abstract][Full Text] [Related]
3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
4. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy.
Terrisse S; Zitvogel L; Kroemer G
Microb Cell; 2022 Dec; 9(12):202-206. PubMed ID: 36483309
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota-derived short-chain fatty acids promote prostate cancer progression via inducing cancer cell autophagy and M2 macrophage polarization.
Liu Y; Zhou Q; Ye F; Yang C; Jiang H
Neoplasia; 2023 Sep; 43():100928. PubMed ID: 37579688
[TBL] [Abstract][Full Text] [Related]
7. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
Terrisse S; Goubet AG; Ueda K; Thomas AM; Quiniou V; Thelemaque C; Dunsmore G; Clave E; Gamat-Huber M; Yonekura S; Ferrere G; Rauber C; Pham HP; Fahrner JE; Pizzato E; Ly P; Fidelle M; Mazzenga M; Costa Silva CA; Armanini F; Pinto F; Asnicar F; Daillère R; Derosa L; Richard C; Blanchard P; Routy B; Culine S; Opolon P; Silvin A; Ginhoux F; Toubert A; Segata N; McNeel DG; Fizazi K; Kroemer G; Zitvogel L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296557
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
[TBL] [Abstract][Full Text] [Related]
9. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
Li JKM; Wang LL; Wong CYP; Chiu PKF; Teoh JYC; Kwok HSW; Leung SCH; Wong SH; Tsui SKW; Ng CF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1063-1072. PubMed ID: 33850270
[TBL] [Abstract][Full Text] [Related]
10. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
11. [Effects of androgen deprivation therapy for prostate cancer on gut microbiota and treatment].
Liu JY; Zhu YP; Han BM; Xia SJ
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(2):84-88. PubMed ID: 36597735
[TBL] [Abstract][Full Text] [Related]
12. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.
Sfanos KS; Markowski MC; Peiffer LB; Ernst SE; White JR; Pienta KJ; Antonarakis ES; Ross AE
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):539-548. PubMed ID: 29988102
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
Elishmereni M; Kheifetz Y; Shukrun I; Bevan GH; Nandy D; McKenzie KM; Kohli M; Agur Z
Prostate; 2016 Jan; 76(1):48-57. PubMed ID: 26419619
[TBL] [Abstract][Full Text] [Related]
15. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Pernigoni N; Zagato E; Calcinotto A; Troiani M; Mestre RP; Calì B; Attanasio G; Troisi J; Minini M; Mosole S; Revandkar A; Pasquini E; Elia AR; Bossi D; Rinaldi A; Rescigno P; Flohr P; Hunt J; Neeb A; Buroni L; Guo C; Welti J; Ferrari M; Grioni M; Gauthier J; Gharaibeh RZ; Palmisano A; Lucchini GM; D'Antonio E; Merler S; Bolis M; Grassi F; Esposito A; Bellone M; Briganti A; Rescigno M; Theurillat JP; Jobin C; Gillessen S; de Bono J; Alimonti A
Science; 2021 Oct; 374(6564):216-224. PubMed ID: 34618582
[TBL] [Abstract][Full Text] [Related]
16. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis.
Na AY; Choi S; Yang E; Liu KH; Kim S; Jung HJ; Choe Y; Ha YS; Kwon TG; Lee JN; Lee S
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298646
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
20. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
